

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	446	emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:16
S2	210	S1 and cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:41
S3	59	S2 and (phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:41
S4	1	S3 and dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:43
S5	33	S3 and (tyrosine adj1 kinase)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S6	0	S5 and (emodin with (phospholipd or phosphatidylcholine))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:49
S7	0	(emodin with (phospholipd or phosphatidylcholine))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S8	0	trihydroxyanthraquinonoe	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S9	99	trihydroxyanthraquinone	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S10	11	S9 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:02
S11	2	"6395712".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:03
S12	1	S11 and (emodin or liposome or phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:05

S13	0	S12 and dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:05
S14	1	S12 and glycerol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:10
S15	2	"20020156062".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:10
S16	2	S15 and (emodin or lipid or phospholipid or lecithin or dimyristol or phosphatidylcholine or cancer or leukemia)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:13
S17	1	S15 and (emodin and dimyristoyl)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:14
S18	3	(emodin and dimyristoyl)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:14
S19	2	"5053431".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:16
S20	2	"5316768".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S21	2	"5466455".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S22	2	"6326356".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S23	2	"6328988".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:18
S24	1	S23 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19

S25	2	"5514714".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19
S26	1	S25 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19
S27	2	"6444234".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:20
S28	1	S27 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:20
S29	446	emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S30	210	S29 and cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S31	59	S30 and (phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:28
S32	33	S31 and (tyrosine adj1 kinase)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S33	32	S32 and (surfactant or Tween or soybean or peanut or detergent)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:28
S34	359	claxton.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:42
S35	3	S34 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:43
S36	7110	newman.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:44

S37	4	S36 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:45
S38	0	lopez-berenstein.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S39	0	(lopez adj1 berenstein).in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S40	70	(lopez-berenstein).in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S41	3	S40 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:47
S42	2	"6197754".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:16
S43	1	S42 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:55
S44	1	S42 and (surfactant or dmpg or dmpc or phosphatidylcholine or glycerol or soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:45
S45	2	"6395712".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:19
S46	1	S45 and (surfactant or dmpg or dmpc or phosphatidylcholine or glycerol or soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:19
S47	1	S42 and (emodin or dmpg or dmpc or phosphatidylcholine or surfactant or soybean or peanut or tween or dimyristol or glycerol)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:18
S48	13	dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:23

S49	1	S48 and (emodin or anthraquinone)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:19
S50	1	S48 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:28
S51	66	tween and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:28
S52	19	S51 and (soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:44
S53	3146	424/450.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:44
S54	13	S53 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:45
S55	177049	(liposome or lipid or lecithin or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:46
S56	13	S54 and S55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:59
S57	0	WO200290313.pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:00
S58	0	WO02/90313.ptpn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:00
S59	156	boch.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29
S60	1	S59 and hydrophobic.ti.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29

S61	0	S60 and tween	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29
S62	1	S60 and surfactant	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:30
S63	1	S60 and (soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:32
S64	1747	dimyristoyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:33
S65	3	S64 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:10
S66	617	514/569.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:11
S67	7	S66 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:12
S68	468	424/455.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:14
S69	0	S68 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:15
S70	18	anthraquinone with liposome	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:23
S71	49	emodin.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:49
S72	4830	liposome.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:23

S73	1	S72 and S71	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:27
S74	0	S70 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:27
S75	2	"4377567".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:53
S76	1	S75 and dimyristoyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 14:48
S77	0	("4481185".pn. and (cholesterol or fatty or glycol or diglyceried or sterol))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:23
S78	0	tween with preferred	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:28
S79	3623	Tween with detergent	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:29
S80	0	S79 and (tween with preferred)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:30
S81	0	S79 and (tween same preferred)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:30

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	19238	((sorbitan with ester) with (detergent or surfactant or emulsifier))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:33
S2	11	S1 with liposome	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:34
S3	4	S2 and (tween or monolaurate)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:35
S4	5826	S1 and lecithin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:36
S5	1330	S4 and tween	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:36

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:saptaeval647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 28 PATDPAPFULL - New display fields provide for legal status
data from INFADOC
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/REGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/REGISTRY
NEWS 10 MAR 22 PATDPAPPC - New patent database available
NEWS 11 MAR 22 REGISTRY/REGISTRY enhanced with experimental property tags
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new
fields
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced
NEWS 14 APR 18 New CAS Information Use Policies available online
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),
based on application date in CA/CAPLUS and USPATFULL/USPAT2
may be affected by a change in filing date for U.S.
applications
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for
U.S. patent records in CA/CAPLUS
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from
CHEMCATS
NEWS 19 JUN 06 The Analysis Edition of STN Express with Discover!
(Version 8.0 for Windows) now available
NEWS 20 JUN 13 RUSSSIAPAT: New full-text patent database on STN
NEWS 21 JUN 13 PFULL enhanced with patent drawing images
NEWS 22 JUN 27 KOREPAT displays enhanced with expanded G-group definitions
and text labels
NEWS 23 JUL 01 MEDICCONF removed from STN
NEWS 24 JUL 07 STN Patent Forums to be held in July 2005
NEWS 25 JUL 13 SCISEARCH reloaded
NEWS 26 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 27 AUG 11 Derwent World Patents Index(R) web-based training during
August
NEWS 28 AUG 11 STN AnaVist workshops to be held in North America

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V9.0.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0c(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

=> s emodin
L1 85 EMODIN

=> file hcaplus uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 5.03 5.24

FILE 'HCAPLUS' ENTERED AT 12:56:07 ON 22 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s emodin
L2 2361 EMODIN

=> s dimyristoyl
L3 3796 DIMYRISTOYL

=> s l2 and l3
L4 4 L2 AND L3

=> d l4 1-4 ibib abs

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 1991:446028 HCAPLUS Full-text
DOCUMENT NUMBER: 115:46028
TITLE: Lipids from fruits of Rumex paulsenianus
AUTHOR(S): Guskova, S. D.; Khomova, T. V.; Glushenkova, A. I.
CORPORATE SOURCE: Inst. Khim. Rastit. Veshchestv, USSR
SOURCE: Khimiya Prirodnikh Soedinenii (1990), (5), 604-11
CODEN: KPSUAR; 1990: 0023-1150
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Seeds and pericarp comprised 29 and 71 wt.% of R. paulsenianus fruit and
contained 7.8 and 0.58% lipids, resp. Thus, the pericarp contribution to
fruit lipids was \$15 weight%. The fruit and seed lipids were almost
identical. The fruits contained 11 saturated, and 4 mono-, 2 di-, and one
(18:3) trienic free fatty acids. The triacylglycerides contained 2 rare
monoaceto compds.: 1,3-dimyristoyl-2-acetyl- and 1-myristoyl-2-capronoyl-3-
acetyl-sn-glyceride, and 1,3-dimyristoyl-2-capronoylglyceride. C27, C29, and
C31 comprised 578% of fruit paraffins. Fatty alcs. were 23:0-32:0 alkanols,
the major ones being 24:0 and 26:0. The major free sterol was β -sitosterol.
It was followed by campesterol and stigmastanol. The identified
anthraquinones, chrysophanol, physcion and aloe-emodin, were higher in the
pericarp than in the seeds.

L4 ANSWER 2 OF 4 USPATFULL ON STN
ACCESSION NUMBER: 2005:10532 USPATFULL Full-text
TITLE: Compositions and methods related to lipid:
emodin formulations
INVENTOR(S): Claxton, David, Hummelstown, PA, UNITED STATES
Newman, Robert A., Houston, TX, UNITED STATES
Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S.)

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8
DICTIONARY FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

corporation)
The Penn State Research Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005008664	A1	20050113
APPLICATION INFO.:	US 2003-730361	A1	20031208 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431422P	20021206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1078	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the use of methods and compositions to
provide an improved lipid:emodin formulation for the treatment of leukemias
expressing bcr-abl and other cancer with elevated tyrosine kinase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 4 USPATFULL ON STN
ACCESSION NUMBER: 2002:280616 USPATFULL Full-text
TITLE: Drug delivery system for hydrophobic drugs
INVENTOR(S): Boch, Ronald Erwin, Vancouver, CANADA
Singh, Dev Mitra Ranji, Surrey, CANADA
Kermadi, Iman, Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156062	A1	20021024
APPLICATION INFO.:	US 2001-831406	A1	20010411 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1930		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising microaggregates containing hydrophobic drugs, as
well as methods for their production, are described. Such microaggregates
may include micelle structures or combinations thereof with liposomes, and
constitute an effective delivery vehicle for a hydrophobic agent. Methods
for microaggregate production include the use of preferred lipid compounds
and processing conditions favoring the production of small aggregates for
improved filter sterilization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 4 USPATFULL ON STN
ACCESSION NUMBER: 2002:119350 USPATFULL Full-text

TITLE: Supports for photosensitizer formulations
INVENTOR(S): Chowdhary, Rubinah K., Vancouver, CANADA
Dolphin, David, Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061330	A1	20020523
APPLICATION INFO.:	US 2001-851606	A1	20010508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-202640P	20000508 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Kawai Lau, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3401	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is generally related to the field of formulating medicaments in association with a solid support. Such formulations comprising photosensitizers, and their use in photodynamic therapy, are also provided. Methods for the production of the medicament formulations are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s lecithin or phospholipid or liposome or phosphatidylcholine
L5 209410 LECITHIN OR PHOSPHOLIPID OR LIPOsome OR PHOSPHATIDYLCHOLINE

=> s L1 and L5
L6 620 L1 AND L5

=> s L6 and tween
L7 148 L6 AND TWEEN

=> s L7 and (soybean or peanut)
L8 78 L7 AND (SOYBEAN OR PEANUT)

=> s L8 and (dmcp or dmpp or glycerol)
L9 70 L8 AND (DMCP OR DMPP OR GLYCEROL)

=> s L9 and phosphatidylcholine
L10 30 L9 AND PHOSPHATIDYLCHOLINE

=> dup rem
ENTER L# LIST OR (END):110
PROCESSING COMPLETED FOR L10
L11 30 DUF REM L10 (0 DUPLICATES REMOVED)

=> d 111 20-30 ibib abs

L11 ANSWER 20 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:167866 USPATFULL Full-text
TITLE: Acoustically active drug delivery systems
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compositions by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compositions of the invention are particularly suitable for use in oral dosage forms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:144937 USPATFULL Full-text
TITLE: Solid matrix therapeutic compositions
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
PATENT ASSIGNEE(S): InaRx Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018072	A1	20010830
APPLICATION INFO.:	US 2001-828762	A1	20010409 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4899	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:190748 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine Inc., Salt Lake City, UT, United States (U.S. corporation)

PATENT ASSIGNEE(S): Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6416740	B1	20020709
APPLICATION INFO.:	US 1998-75343		19980511 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dudash, Diana	
ASSISTANT EXAMINER:	Sharareh, Shahnaim	
LEGAL REPRESENTATIVE:	Woodcock Washburn LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	5660	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:102011 USPATFULL Full-text
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, United States
Patel, Mahesh V., Salt Lake City, UT, United States
Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383471	B1	20020507
APPLICATION INFO.:	US 1999-287043		19990406 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Bawa, Rej		
LEGAL REPRESENTATIVE:	Reed, Dianne E., Reed & Associates		
NUMBER OF CLAIMS:	114		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	3051		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION: US 6309663 B1 20011030
APPLICATION INFO.: US 1999-375636 19990817 (9)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Channavajjala, Lakshmi
LEGAL REPRESENTATIVE: Reed, Dianne E. Reed & Associates
NUMBER OF CLAIMS: 170
EXEMPLARY CLAIM: 1
LINE COUNT: 4371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions, pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. Compositions and systems of the present invention include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compositions and systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:162866 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294192	B1	20010925
APPLICATION INFO.:	US 1999-258654		19990226 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Channavajjala, Lakshmi		
LEGAL REPRESENTATIVE:	Reed, Dianne E. Reed & Associates		
NUMBER OF CLAIMS:	74		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	3094		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 30 USPATFULL on STN

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 30 USPATFULL on STN
ACCESSION NUMBER: 97:45047 USPATFULL Full-text
TITLE: Cytoprotective wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5633285		19970527
US 1995-446962		19950522 (8)
Continuation-in-part of Ser. No. US 1994-312841, filed on 27 Sep 1994, now abandoned which is a continuation of Ser. No. US 1992-841342, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Barish, Jean B.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 62 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 4208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic cytoprotective-wound healing compositions. The compositions comprise a cytotoxic agent and a therapeutic wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. In another embodiment the wound healing composition comprises (a) pyruvate; and, (b) an antioxidant. The therapeutic cytoprotective-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic cytoprotective-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

--> d 111 10-19 ibib abs

L11 ANSWER 10 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:239241 USPATFULL Full-text
TITLE: FcgammaRIIb-specific antibodies and methods of use thereof
INVENTOR(S): Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Marie Concetta, Derwood, MD, UNITED STATES
PATENT ASSIGNEE(S): MacroGenics, Inc. (U.S. corporation)

NUMBER	KIND	DATE
US 2004185045	A1	20040923
US 2003-643857	A1	20030814 (10)

NUMBER	DATE
--------	------

performed into a device or is applied as a coating to a surface of a more complex drug delivery system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:120135 USPATFULL Full-text
TITLE: Solid matrix therapeutic compositions
INVENTOR(S): Unger, Evan C., Tucson, AZ, UNITED STATES

NUMBER	KIND	DATE
US 2004091541	A1	20040513
US 2003-622027	A1	20030716 (10)

Continuation of Ser. No. US 2001-828762, filed on 9 Apr 2001, ABANDONED Division of Ser. No. US 1998-75477, filed on 11 May 1998, ABANDONED

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-46379P 19970513 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 4909

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:94315 USPATFULL Full-text
TITLE: NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
INVENTOR(S): Cevc, Gregor, Gauting, GERMANY, FEDERAL REPUBLIC OF
Vierl, Ulrich, Munchen, GERMANY, FEDERAL REPUBLIC OF

NUMBER	KIND	DATE
US 2004071767	A1	20040415
US 2003-357617	A1	20030204 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-417847P 20021011 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA,

PRIORITY INFORMATION: US 2002-403266P 20020814 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 107
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 7320

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIb, particularly human FcγRIIb, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:196470 USPATFULL Full-text
TITLE: Therapeutic compositions for drug delivery to and through covering epithelia
INVENTOR(S): Pauletti, Giovanni M., Loveland, OH, UNITED STATES
Desai, Kishorkumar J., Westchester, OH, UNITED STATES
Roweton, Susan L., Raleigh, NC, UNITED STATES
Harrison, Donald C., Cincinnati, OH, UNITED STATES
Sanders, Lynda M., Los Altos, CA, UNITED STATES

NUMBER	KIND	DATE
US 2004151774	A1	20040805
US 2003-698794	A1	20031031 (10)

Continuation-in-part of Ser. No. US 2003-444634, filed on 22 May 2003, PENDING

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-425655P 20021112 (60)
US 2002-423260P 20021031 (60)
US 2002-424920P 20021108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HANA VERNY, PETERS, VERNY, JONES & SCHMITT, L.L.P., SUITE 230, 425 SHERMAN AVENUE, PALO ALTO, CA, 94306
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 2483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymer foams and films for delivery of therapeutic agents to and through nasal, oral or vaginal mucosa and cornified or non-cornified epithelium of labia and scrotum. Polymer foams or absorbable or non-absorbable films containing a therapeutic agent incorporated therein wherein said agent is released from said foams or films upon placement of said foam or film on the surface epithelium of nasal, oral, or vaginal labia or scrotum. The foam or the film has a controllable rate of gelling, swelling and degradation and is

02205
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1824

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipathic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionized NSAID is one of the two, amongst said three, components that tends to destabilize lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipathic components typically forms a stable lipid membrane on its own. An essential characteristic of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:306064 USPATFULL Full-text
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

NUMBER	KIND	DATE
US 2003215496	A1	20031120
US 6923988	B2	20050802
US 2003-428341	A1	20030501 (10)

Continuation of Ser. No. US 2001-800593, filed on 6 Mar 2001, GRANTED, Pat. No. US 6564633 Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 81
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3364

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier

including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmetics and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:92739 USPATFULL Full-text
TITLE: SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC
ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064097	A1	20030403
APPLICATION INFO.:	US 6569463	B2	20030527
RELATED APPLN. INFO.:	US 2001-800593	A1	20010306 (9)
	Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363		
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	91		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	3863		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmetics and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:28704 USPATFULL Full-text
TITLE: Novel acoustically active drug delivery systems
INVENTOR(S): Unger, Evan C., Tucson, AZ, UNITED STATES

agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbicide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of entero-bacteria, and to less than 1 in the case of Pseudomonas aeruginosa or Staphylococcus aureus, after a period of 4 days.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:72457 USPATFULL Full-text
TITLE: SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
INVENTOR(S): UNGER, EVAN C., TUCSON, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002039594	A1	20020404
APPLICATION INFO.:	US 1998-75477	A1	19980511 (9)

	NUMBER	KIND	DATE
PRIORITY INFORMATION:	US 1997-46379P		19970513 (60)
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103		
NUMBER OF CLAIMS:	106		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	5207		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a solvent and a surfactant in combination with a bioactive agent. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprises the matrix. The composition optionally comprises a gas or a gaseous precursor. The emulsion may be dried, and subsequently reconstituted in an aqueous or organic solution.

The present invention is also directed to a method of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprise a gas or gaseous precursor and be added to a resuspending medium.

A method for the controlled delivery of a targeted therapeutic to a region of a patient is another embodiment of the present invention. The method comprises administering to the patient a composition having a solid porous matrix comprising a solvent, a surfactant, a therapeutic, and a gas or gaseous precursor, monitoring the composition using energy to determine the

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002159952	A1	20021031
APPLICATION INFO.:	US 2002-84855	A1	20020227 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-75343, filed on 11 May 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103	

NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:126014 USPATFULL Full-text
TITLE: Formulation for topical non-invasive application in vivo
INVENTOR(S): Cevc, Gregor, Kirchheim, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002064524	A1	20020530
APPLICATION INFO.:	US 2001-987493	A1	20010622 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-EP8421, filed on 23 Dec 1998, UNKNOWN		
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 14th Floor, 485 Seventh Avenue, New York, NY, 10018		
NUMBER OF CLAIMS:	50		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	1846		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or else enable

presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:21845 USPATFULL Full-text
TITLE: Compositions and methods for improved delivery of lipid regulating agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012680	A1	20020131
APPLICATION INFO.:	US 6451339	B2	20020917
RELATED APPLN. INFO.:	US 2001-898553	A1	20010702 (9)
	Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192		
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	140		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	3604		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

--> d his full

(FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005)

L1 FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
85 SEA EMODIN

L2 FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005

L3 2361 SEA EMODIN
L4 3796 SEA DIMYRISTOYL
L5 4 SEA L2 AND L3
D L4 1-4 IBS ABS
L6 209410 SEA LECITHIN OR PHOSPHOLIPID OR LIPOSOOME OR PHOSPHATIDYLCHOLINE
L7 620 SEA L1 AND L5
L8 148 SEA L6 AND TWEEN
L9 78 SEA L7 AND (SOYBEAN OR PEANUT)
70 SEA L8 AND (DMPC OR DMPG OR GLYCEROL)

L10 30 SEA L9 AND PHOSPHATIDYLCHOLINE
L11 30 DUP REM L10 (0 DUPLICATES REMOVED)
D L11 20-30 IBIB ABS
D L11 10-19 IBIB ABS

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the IIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8
DICTIONARY FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2005 VOL 143 ISS 9
FILE LAST UPDATED: 21 Aug 2005 (20050821/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Aug 2005 (20050818/PD)
FILE LAST UPDATED: 18 Aug 2005 (20050818/ED)
HIGHEST GRANTED PATENT NUMBER: US6931661
HIGHEST APPLICATION PUBLICATION NUMBER: US2005183181
CA INDEXING IS CURRENT THROUGH 18 Aug 2005 (20050818/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Aug 2005 (20050818/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THE SAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the FI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /FN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<

>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l11 1-9 ibib abs

L11 ANSWER 1 OF 30 USPATFULL on STN

ACCESSION NUMBER:

TITLE: 2005:177866 USPATFULL Full-text
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

INVENTOR(S):

Padval, Mahesh, Waltham, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fung, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmerman, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005153947 A1 20050714
APPLICATION INFO: US 2004-947455 A1 20040920 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-777517, filed on 12 Feb 2004, PENDING Continuation-in-part of Ser. No. US

2003-670488, filed on 24 Sep 2003, PENDING

PRIORITY INFORMATION: US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427424P 20021119 (60)
US 2002-427526P 20021119 (60)
US 2003-464753P 20030423 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 2921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2005:165911 USPATFULL Full-text
TITLE: Methods and compositions for improved non-viral gene therapy
INVENTOR(S): Ramesh, Rajagopal, Sugar Land, TX, UNITED STATES
Gopalan, Began, Houston, TX, UNITED STATES
Roth, Jack A., Houston, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

NUMBER KIND DATE
PRIORITY INFORMATION: US 2005143336 A1 20050630
APPLICATION INFO.: US 2004-341 A1 20041130 (11)

NUMBER DATE
PRIORITY INFORMATION: US 2003-533180P 20031230 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701, US
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 4301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject, that include administering to the subject a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent with the lipid-nucleic acid complex are disclosed. Also disclosed are methods of

screening for inhibitors of the inflammatory response associated with administration of a lipid-nucleic acid complex to a subject, including providing a candidate substance suspected of preventing or inhibiting the inflammation associated with administration of a lipid-nucleic acid complex to the subject. Also disclosed are compositions that include a lipid, a nucleic acid, and a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2005:143867 USPATFULL Full-text
TITLE: Rifalaxil formulations
INVENTOR(S): Michaelis, Arthur F., Devon, PA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005123602 A1 20050609
APPLICATION INFO.: US 2004-950917 A1 20040927 (10)

NUMBER DATE
PRIORITY INFORMATION: US 2003-506107P 20030925 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1636
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features pharmaceutical compositions including rifalaxil and a micelle-forming excipient and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2005:138510 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of immunoinflammatory disorders
INVENTOR(S): Keith, Curtis, Boston, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES
Hurst, Nicole, Boston, MA, UNITED STATES
Foley, Michael A., Chestnut Hill, MA, UNITED STATES
Slavonic, Michael S., Quincy, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005119160 A1 20050602
APPLICATION INFO.: US 2004-966228 A1 20041015 (10)

NUMBER DATE
PRIORITY INFORMATION: US 2003-512415P 20031015 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
LINE COUNT: 4196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2005:10532 USPATFULL Full-text
TITLE: Compositions and methods related to lipid:emodin formulations
INVENTOR(S): Claxton, David, Hummelstown, PA, UNITED STATES
Newman, Robert A., Houston, TX, UNITED STATES
Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)
The Penn State Research Foundation (U.S. corporation)

NUMBER KIND DATE
PATENT INFORMATION: US 2005008664 A1 20050113
APPLICATION INFO.: US 2003-730361 A1 20031208 (10)

NUMBER DATE
PRIORITY INFORMATION: US 2002-431422P 20021206 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the use of methods and compositions to provide an improved lipid:emodin formulation for the treatment of leukemias expressing bcr-abl and other cancer with elevated tyrosine kinase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:320591 USPATFULL Full-text
TITLE: Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions

PRIORITY INFORMATION: US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427526P 20021119 (60)
US 2002-427424P 20021119 (60)
US 2003-464753P 20030423 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 3245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:286708 USPATFULL Full-text
TITLE: Combination therapy for the treatment of immunoinflammatory disorders
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

NUMBER KIND DATE
PATENT INFORMATION: US 2004224876 A1 20041111
APPLICATION INFO.: US 2004-777518 A1 20040212 (10)

PRIORITY INFORMATION: US 2003-447366P 20030214 (60)
US 2003-447412P 20030214 (60)
US 2003-447415P 20030214 (60)
US 2003-447553P 20030214 (60)
US 2003-447648P 20030214 (60)
US 2003-464753P 20030423 (60)
US 2003-503026P 20030915 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
LINE COUNT: 3770

INVENTOR(S): containing the same
Shelton, David L., Oakland, CA, UNITED STATES
Vergara, German J., Moraga, CA, UNITED STATES
Loo, Carole M., San Mateo, CA, UNITED STATES

NUMBER KIND DATE
PATENT INFORMATION: US 2004253244 A1 20041216
APPLICATION INFO.: US 2004-783730 A1 20040219 (10)

NUMBER DATE
PRIORITY INFORMATION: US 2003-448823P 20030219 (60)
US 2003-448853P 20030219 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & POERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:292760 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES

NUMBER KIND DATE
PATENT INFORMATION: US 2004229849 A1 20041118
APPLICATION INFO.: US 2004-777517 A1 20040212 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING

NUMBER DATE

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:280852 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, W. Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES

NUMBER KIND DATE
PATENT INFORMATION: US 2004220153 A1 20041104
APPLICATION INFO.: US 2003-670488 A1 20030924 (10)

NUMBER DATE
PRIORITY INFORMATION: US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427526P 20021119 (60)
US 2003-464753P 20030423 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
LINE COUNT: 3183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his full

(FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005)

FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
85 SEA EMODIN

L1 FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005

L2 2361 SEA EMODIN

L3 3796 SEA DIMYRISTOYL

L4 4 SEA L2 AND L3

L5 D L4 1-4 IBIS ABS

L6 209410 SEA LECITHIN OR PHOSPHOLIPID OR LIPOSOME OR PHOSPHATIDYLCHOLINE

L7 620 SEA L1 AND L5

L8 148 SEA L6 AND TWEEN

L9 78 SEA L7 AND (SOYBEAN OR PEANUT)

L10 70 SEA L8 AND (DMPC OR DMG OR GLYCEROL)

L11 30 SEA L9 AND PHOSPHATIDYLCHOLINE

L12 30 DUP REM L10 (0 DUPLICATES REMOVED)

L13 D L11 20-30 IBIS ABS

L14 D L11 10-19 IBIS ABS

L15 D L11 1-9 IBIS ABS

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8

DICTIONARY FILE UPDATES: 19 AUG 2005 HIGHEST RN 861198-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

.....
*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information.
*
.....

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Aug 2005 VOL 143 ISS 9

FILE LAST UPDATED: 21 Aug 2005 (20050821/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Aug 2005 (20050818/PD)

FILE LAST UPDATED: 18 Aug 2005 (20050818/ED)

HIGHEST GRANTED PATENT NUMBER: US6931661

HIGHEST APPLICATION PUBLICATION NUMBER: US2005183181

CA INDEXING IS CURRENT THROUGH 18 Aug 2005 (20050818/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Aug 2005 (20050818/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	98.19	103.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:06:02 ON 22 AUG 2005